why does nobody talk about survodutide
Trying to get a straight answer on this: why does nobody talk about survodutide. Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it. Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed…
Left up. It reads the paper carefully and is explicit about the population.
research material is not approved for human use, which is why the clinical record here is thin
biopsy-confirmed is not the same as imaging-suggested
dual GLP-1 and glucagon agonist, and the glucagon arm is the story
What does the tolerability table say at that dose?
Yes — histological endpoints are a far harder bar than the surrogate measures people are used to quoting.
This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.
read the histology endpoint definitions before quoting a response rate
phase 2 in liver disease is a different evidence question from weight
not approved anywhere, and the boards forget that constantly
Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.